Advertisement


Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement



Dec
06
Today In Oncology
Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer
First-Line Treatment of Advanced HCC Addition of Pembrolizumab to Lenvatinib
Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma
Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors
Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy
View More 
Advertisement
© 2023 HSP News Service, L.L.C.
Designed by Harborside